• Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page

Acadia's prized pain drug from $52M buyout flops its first test

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Apr 19, 2022 at 11:12: AM
via When Acadia Pharmaceuticals put down $52.5 million in cash to buy out CerSci Therapeutics – along with $887 million in biobucks – in 2020, CEO Steve Davis made clear that its non-opioid painkillers for acute and chronic pain, particularly the lead compound, ACP-044, was the star of the show. A Phase II study was being planned for the following year.

article source
 




Top Bottom
Back
Quote